Lifeward (NASDAQ:LFWD) Releases Quarterly Earnings Results, Misses Expectations By $5.52 EPS

Lifeward (NASDAQ:LFWD) released its quarterly earnings results on Friday. The company reported ($6.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($5.52), Zacks reports. The company had revenue of $3.92 million for the quarter, compared to the consensus estimate of $5.78 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 213.99%.

Here are the key takeaways from Lifeward’s conference call:

• Lifeward completed the Oratech acquisition, which management says expands the company into a more diversified biomedical innovation platform and gives shareholders exposure to the oral protein delivery technology with limited near-term operating burden.
• The company raised $10 million through convertible note financing and added cash from the transaction, ending Q1 2026 with $11.4 million in unrestricted cash versus $2.2 million at year-end 2025.
• First-quarter revenue fell to $3.9 million from $5.0 million, mainly because AlterG shipments were delayed by manufacturing, sourcing, and working capital issues during the transition to contract manufacturing.
• ReWalk personal exoskeleton revenue rose 11% year over year to $1.6 million, helped by reimbursement progress, distribution expansion, and stronger international sales, including nearly 25% growth in Germany.
• Management expects AlterG shipments to improve in the second and third quarters as backlog is worked down, and reiterated that 2026 revenue should be similar to 2025 despite a weak first quarter.

Lifeward Stock Performance

Shares of LFWD traded up $0.09 during midday trading on Wednesday, hitting $6.49. 3,026 shares of the company traded hands, compared to its average volume of 19,413. The stock has a market cap of $9.92 million, a price-to-earnings ratio of -0.33 and a beta of 0.32. The firm has a 50 day moving average of $6.79 and a 200-day moving average of $7.04. Lifeward has a 52 week low of $4.14 and a 52 week high of $15.84.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LFWD. Weiss Ratings restated a “sell (e+)” rating on shares of Lifeward in a research note on Tuesday, April 21st. HC Wainwright raised their price target on Lifeward to $10.00 and gave the company a “buy” rating in a report on Thursday, March 19th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of Lifeward

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC increased its position in shares of Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after acquiring an additional 198,406 shares during the period. HRT Financial LP grew its stake in Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after purchasing an additional 29,423 shares in the last quarter. Jane Street Group LLC grew its stake in Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after purchasing an additional 29,927 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in Lifeward by 158.0% during the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares during the period. Hedge funds and other institutional investors own 26.76% of the company’s stock.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.